Gabapentin has Longer-term Efficacy for Treatment of Chronic Pelvic Pain in Women: A Systematic Review and Pilot Meta-analysis

Supplementary Online Content

| Table of Contents                                      |       |
|-------------------------------------------------------|-------|
| **eMethods 1:** PubMed Search Strategy Search strategy | Page 2-4 |
| **eMethods 2:** Web of Science Search Strategy Search strategy | Page 5 |
| **eMethods 3:** EMBASE Search Strategy Search strategy  | Page 5 |
| **eMethods 4:** Cochrane Library Search Strategy Search strategy | Page 5 |
| **eMethods 5:** Google Scholar Search Strategy Search strategy | Page 5 |
| **Figure S1:** Risk of Bias Summary                   | Page 6 |
| **Figure S2:** Cross Tabulation Risk of Bias          | Page 7 |
| **Table S1:** PRISMA Checklist                         | Page 8-9 |
### PubMed (7)

| Subject words:          | Free words                                                                 |
|-------------------------|-----------------------------------------------------------------------------|
| Gabapentin              | 1-(Aminomethyl)cyclohexaneacetic Acld                                               |
|                         | Neurontin                                                                   |
|                         | Gabapentin Hexal                                                            |
|                         | Convalis                                                                    |
|                         | Gabapentin-Ratiopharm                                                        |
|                         | Gabapentin Ratiopharm                                                        |
|                         | Novo-Gabapentin                                                             |
|                         | Novo Gabapentin                                                             |
|                         | NovoGabapentin                                                              |
|                         | PMS-Gabapentin                                                              |
|                         | Apo-Gabapentin                                                              |
|                         | Apo Gabapentin                                                              |
|                         | ApoGabapentin                                                               |
|                         | Gabapentin Stada                                                            |
|                         | chronic pelvic pain                                                         |
|                         | CPP                                                                         |
| Randomized Controlled Trial | randomized                                                                 |
| [Publication Type]      | placebo                                                                    |
1. "Gabapentin"[Mesh] (3896)
2. ((((((((((1-(Aminomethyl)cyclohexaneacetic Acid[Title/Abstract]) OR (Neurontin[Title/Abstract])) OR (Gabapentin Hexal[Title/Abstract])) OR (Convalis[Title/Abstract])) OR (Gabapentin-Ratiopharm[Title/Abstract])) OR (Gabapentin Ratiopharm[Title/Abstract])) OR (Novo-Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo-Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (PMS-Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Gabapentin Stada[Title/Abstract])) (218)
3. ("Gabapentin"[Mesh]) OR (((((((((((1-(Aminomethyl)cyclohexaneacetic Acid[Title/Abstract]) OR (Neurontin[Title/Abstract])) OR (Gabapentin Hexal[Title/Abstract])) OR (Convalis[Title/Abstract])) OR (Gabapentin-Ratiopharm[Title/Abstract])) OR (Gabapentin Ratiopharm[Title/Abstract])) OR (Novo-Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (PMS-Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Gabapentin Stada[Title/Abstract])) (3961)
4. (chronic pelvic pain[Title/Abstract]) OR (CPP[Title/Abstract]) (14614)
5. "randomized controlled trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] (883268)
6. ((("Gabapentin"[Mesh]) OR (((((((1-(Aminomethyl)cyclohexaneacetic Acid[Title/Abstract]) OR (Neurontin[Title/Abstract])) OR (Gabapentin Hexal[Title/Abstract])) OR (Convalis[Title/Abstract])) OR (Gabapentin-Ratiopharm[Title/Abstract])) OR (Gabapentin Ratiopharm[Title/Abstract])) OR (Novo-Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR (PMS-Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Gabapentin Stada[Title/Abstract])) OR (Neurontin[Title/Abstract])) OR (Gabapentin
Hexal[Title/Abstract]) OR (Convalis[Title/Abstract])) OR (Gabapentin-Ratiopharm[Title/Abstract])) OR (Gabapentin Ratiopharm[Title/Abstract])) OR  
(Novo-Gabapentin[Title/Abstract])) OR (Novo Gabapentin[Title/Abstract])) OR  
(NovoGabapentin[Title/Abstract])) OR (PMS-Gabapentin[Title/Abstract])) OR (Apo-Gabapentin[Title/Abstract])) OR (Apo Gabapentin[Title/Abstract])) OR  
(ApoGabapentin[Title/Abstract])) OR (Gabapentin Stada[Title/Abstract])))) AND  
((chronic pelvic pain[Title/Abstract]) OR (CPP[Title/Abstract]))) AND ("randomized controlled trial"[Publication Type] OR "randomized"[Title/Abstract] OR"placebo"[Title/Abstract]) (7)
**Web of Science (11)**

| Query | Results |
|-------|---------|
| TS=(Randomized controlled trial or randomized or placebo) | 11 |
| TS=(chronic pelvic pain or CPP) | 523,153 |
| TS=(Gaba or Gabapentin-Ratiopharm or Gabapentin Ratiopharm or Novo-Gabapentin or Novo Gabapentin or Gabapentin HX or Neurontin or 1-Aminomethylcyclohexaneacetic Acid or NeuraxGabapentin or PMS) | 9,719 |
| TS=(Gaba or Gabapentin) | 4,262 |

**Embase (23)**

| Query | Results |
|-------|---------|
| #5: randomized controlled trial OR placebo OR randomized | 904,251 |
| #4: chronic pelvic pain OR CPP | 20,114 |
| #3: #1 OR #2 | 31,960 |
| #2: 1-Aminomethylcyclohexaneacetic acid OR neurontin OR gabapentin hexal OR convalse OR gabapentin-ratiopharm OR gabapentin ratipharma OR nova-gabapentin OR novogabapentin OR pms-gabapentin OR apo-gabapentin OR apo gabapentin OR apo gabapentin OR apogabapentin | 269 |
| #1: gabapentin | 31,952 |

**Cochrane Library (11)**

| Query | Results |
|-------|---------|
| #1: Medline descriptor: Gabapentin explode all trees | 864 |
| #2: Neurontin OR Gabapentin Hexal OR Convalse OR Gabapentin Ratipharma OR Nova Gabapentin OR Novo Gabapentin OR Gabapentin HX OR Neurontin OR 1-Aminomethylcyclohexaneacetic Acid OR NeuraxGabapentin OR PMS-Gabapentin OR Apo-Gabapentin OR Apo Gabapentin OR Apo Gabapentin OR Apogabapentin | 97 |
| #3: #1 OR #2 | 931 |
| #4: chronic pelvic pain OR CPP | 3659 |
| #5: randomized controlled trial OR randomized OR placebo | 1154054 |
| #6: #3 AND #4 AND #5 | 11 |

**Google Scholar (100)**

Gabapentin AND chronic pelvic pain AND RCT (First ten pages of results (100 citations) included.)
Figure S1: Risk of Bias Summary
Figure S2: Cross Tabulation Risk of Bias

Green circle= low bias risk, yellow circle= unclear bias risk, red circle= high bias risk.
## Table S1: PRISMA Checklist

| Section/topic | # | Checklist item                                                                                                                                                                                                 | Reported on page # |
|---------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| **TITLE**     |   |                                                                                                                                                                                                                           |                   |
| Title         | 1 | Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                     | Page 1            |
| **ABSTRACT**  |   |                                                                                                                                                                                                                           |                   |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Page 2~3         |
| **INTRODUCTION** |   |                                                                                                                                                                                                                          |                   |
| Rationale     | 3 | Describe the rationale for the review in the context of what is already known.                                                                                                                                           | Page 4            |
| Objectives    | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                              | Page 4~5         |
| **METHODS**   |   |                                                                                                                                                                                                                           |                   |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                                  | Page 6            |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                               | Page 6~7         |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                  | Page 6            |
| Search        | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                             | Page 6            |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                | Page 6~7         |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | Page 7 |
|-------------------------|----|----------------------------------------------------------------------------------------------------------------------------------|--------|
| Data items              | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | Page 8–9 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | Page 7–8 |
| Summary measures        | 13 | State the principal summary measures (e.g., risk ratio, difference in means).                                                  | Page 9 |
| Synthesis of results    | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis. | Page 9–10 |